|
|
Article: Oral calcitriol: a new therapeutic agent in cutaneous lichen sclerosis.
- Article from:
- Journal of Drugs in Dermatology
- Article date:
- January 1, 2003
- Author:
CopyrightCOPYRIGHT 2003 Journal of Drugs in Dermatology, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Abstract
Background: Lichen sclerosus remains an elusive disease with an uncertain relationship to morphea and scleroderma. The disorder has been difficult to treat, with no consistent and reproducible efficacious therapy. Recently, a beneficial effect of treatment with oral calcitriol (1-25 dihydroxyvitamin D3) in patients with scleroderma or morphea was described. This fact could be ascribed to the immunomodulatory effects of calcitriol observed in vitro and to inhibition of fibroblastic growth. Because of the success of calcitriol in localized scleroderma, we attempted this therapy in a patient with LS.
Observation: One patient with cutaneous ...